Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation

Published:2017-06-23 Issue:6 Volume:178 Page:927-935
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Strüßmann Tim¹^ORCID,Fritsch Kristina¹,Baumgarten Axel¹,Fietz Thomas²,Engelhardt Monika¹,Mertelsmann Roland¹,Ihorst Gabriele³,Duyster Justus¹,Finke Jürgen¹,Marks Reinhard¹

Affiliation:

1. Department Haematology, Oncology & Stem Cell Transplantation; Faculty of Medicine and Medical Centre - University of Freiburg; Freiburg Germany

2. Community-based private haematology-oncology practice; Singen Germany

3. Clinical Trials Unit; Faculty of Medicine and Medical Centre - University of Freiburg; Freiburg Germany

Funder

Comprehensive Cancer Centre Freiburg

Faculty of Freiburg (Forschungskommission University of Freiburg)

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14802/fullpdf

Reference33 articles.

1. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma;Abramson;Cancer,2010

2. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 - the Southwest Oncology Group;Bernstein;Journal of Clinical Oncology,2009

3. Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index;Bertz;Annals of Oncology : Official Journal of the European Society for Medical Oncology/ESMO,2004

4. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma;Cheah;British Journal of Cancer,2014

5. Report of an International Workshop to standardize response criteria for non-hodgkin's lymphomas;Cheson;Journal of Clinical Oncology,1999

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma;Expert Review of Anticancer Therapy;2022-05-05

2. Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome;Frontiers in Pharmacology;2022-01-26

3. Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes;Clinical and Translational Science;2021-11-29

4. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis;Blood Advances;2020-05-07

5. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4;Pediatric Hematology and Oncology;2020-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3